Key Points {#d30e177}
==========

Immune checkpoint inhibitors are designed to interrupt inhibitory immune signals and restore immune responses against tumors.Numerous immune checkpoint inhibitors are in advanced stages of development and show activity across multiple tumor types, including advanced melanoma and advanced non-small-cell lung cancer.Understanding the mechanism-associated adverse events and response patterns is important to the management of patients as these drugs are moved into the clinical practice setting.

Introduction {#Sec1}
============

Rudolph Virchow may have been one of the first physicians in modern times to observe the link between the immune system and malignancy in what he termed "lymphoreticular infiltrates". These infiltrates were leukocytes surrounding malignant tumors, and he hypothesized that proinflammatory states might induce normal tissues to become malignant \[[@CR1]\]. Since then, we have learned a great deal about how the immune system responds and reacts to tumors, which tumor-specific antigens are recognized as foreign, and how immune responses can be manipulated and harnessed to enhance tumor cell killing.

Recently, it has been recognized that, on its own, tumor peptide presentation by major histocompatibility complex (MHC) to T-cell receptors is inadequate for successful T-cell activation and immune destruction of cancer cells. Co-regulatory signals, either inhibitory or stimulatory, are also required \[[@CR2], [@CR3]\]. T cells play a critical role in cell-mediated tumor immunity, and do so through an intricate counterbalance of co-stimulatory and co-inhibitory cell-to-cell signals between various components of the immune system. This system of checks and balances is necessary not only to allow a powerful destructive response against both pathogens and malignancies, but also to prevent immune responses from being generated against normal tissues. Critical 'checkpoints' control and fine-tune the immune system through regulation of this complex network of co-stimulatory and co-inhibitory signaling \[[@CR3]\]. In this paper, we review some of the important immune checkpoint molecules elucidated to date, as well as efforts to block these molecules in order to shift the balance towards antitumor immunity. We also describe some of the complexities and challenges encountered using these checkpoint inhibitors in the clinic.

Cytotoxic T-Lymphocyte-Associated Antigen (CTLA)-4 {#Sec2}
==================================================

Background {#Sec3}
----------

More than 40 years of research has led to the development of a two-signal theory of T-cell activation: antigenic stimulation of the T-cell receptor (TCR) (signal 1) together with co-stimulation by other molecules on the cell surface (signal 2) \[[@CR2], [@CR3]\]. One of the key co-stimulatory mechanisms involves the interaction of CD28 on the surface of the T cell with B7 molecules CD80 or CD86 on antigen-presenting cells. CTLA-4, a transmembrane glycoprotein with considerable homology to CD28, binds to the same B7 ligands, as such (Fig. [1](#Fig1){ref-type="fig"}). Upon TCR stimulation by antigens, T cells express CTLA-4, which can bind B7 molecules; however, unlike CD28, CTLA-4 inhibits T-cell responses and is important for maintenance of immune tolerance. Expression of CTLA-4 raises the activation threshold and attenuates clonal expansion; thus, a productive T-cell response ensues only upon a net co-stimulatory signal.Fig. 1T-cell activation and immune checkpoint pathways. T-cell activation requires two signals: (1) presentation of antigenic peptides by MHC to the TCR and (2) co-stimulation, typically via CD28:CD80 or CD28:CD86 ligation. Immune checkpoint pathways comprising receptors on T cells and ligands on antigen-presenting cells and/or tumors fine-tune immune responses via T-cell activation or inhibition. *CTLA-4* cytotoxic T-lymphocyte-associated antigen 4, *GAL9* galectin-9, *GITR* glucocorticoid-induced TNF receptor-related gene, *GITRL* glucocorticoid-induced TNF receptor-related gene ligand, *LAG-3* lymphocyte activation gene-3, *MHC* major histocompatibility complex, *PD-1* programmed death-1, *PD-L1* programmed death ligand 1, *PD-L2* programmed death ligand 2, *TCR* T-cell receptor, *TIM3* T-cell immunoglobulin and mucin domain 3, *TNF* tumor necrosis factor

Efficacy of CTLA-4 Inhibitors {#Sec4}
-----------------------------

### Ipilimumab {#Sec5}

Ipilimumab, one of the best-studied monoclonal antibodies targeting CTLA-4 (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]), has been evaluated in a clinical trial program of more than 2,000 patients with a variety of solid tumors \[[@CR4], [@CR5], [@CR17]--[@CR19]\]. Ipilimumab (Yervoy^®^), administered every 3 weeks for four doses, gained US FDA approval in 2011 for the treatment of unresectable or metastatic melanoma, based on data from two phase III randomized trials showing improvement on median overall survival (OS) over control arms in patients with melanoma \[[@CR4], [@CR5], [@CR20]\]. One of the pivotal phase III trials evaluated ipilimumab with or without gp100 vaccine in previously treated patients with advanced melanoma. Although the best overall response rates were modest, 10.9 % in the ipilimumab-alone group and 5.7 % in the ipilimumab plus gp100 vaccine group, some patients in both groups maintained an objective response for at least 2 years \[[@CR4]\]. In this trial, the 3-year OS rate for ipilimumab monotherapy was 20 % \[[@CR4]\], which compares favorably with the 3-year OS rate of 17 % for historical control patients receiving standard of care chemotherapy in a separate clinical trial \[[@CR21]\] (Table [2](#Tab2){ref-type="table"} \[[@CR4], [@CR5], [@CR7], [@CR18], [@CR19], [@CR21]--[@CR33]\]). The other pivotal phase III trial was conducted in treatment-naïve patients with metastatic melanoma and compared ipilimumab plus dacarbazine versus dacarbazine plus placebo \[[@CR5]\]. Although the dose and schedule were slightly different, the rate of best overall response was 15 % in the ipilimumab plus dacarbazine group versus 10 % for the dacarbazine plus placebo group, while the median duration of response was 19.3 versus 8.1 months for the dacarbazine plus placebo group. Responses lasting at least 2 years were observed in both treatment groups. The 3-year survival rate with ipilimumab plus dacarbazine was significantly higher than dacarbazine plus placebo: 20.8 versus 12.2 % (*P* \< 0.001).Table 1Immune checkpoint inhibitors in clinical development \[[@CR4]--[@CR16]\]NameCompanyDescription of agentIpilimumab \[[@CR4], [@CR5]\]Bristol-Myers SquibbHuman IgG1 mAb against CTLA-4Tremelimumab \[[@CR6]\]MedImmune/AstraZenecaHuman IgG2 mAb against CTLA-4Pembrolizumab (MK-3475) \[[@CR7]\]MerckHumanized IgG4 mAb against PD-1Nivolumab (BMS-936558) \[[@CR8]\]Bristol-Myers SquibbHuman IgG4 mAb against PD-1Pidilizumab (CT-011) \[[@CR9]\]CureTechHumanized IgG1 mAb against PD-1AMP-224 \[[@CR10]\]Amplimmune; GlaxoSmithKlinePD-L2-IgG recombinant fusion proteinMPDL3280A \[[@CR11], [@CR12]\]Genentech/RocheHuman IgG mAb against PD-L1BMS-936559 \[[@CR13]\]Bristol-Myers SquibbHuman IgG4 mAb against PD-L1MEDI4736 \[[@CR14]\]MedImmune/AstraZenecaHuman mAb against PD-L1IMP321 \[[@CR15]\]ImmutepSoluble LAG-3 Ig fusion protein and MHC class II agonistTRX518 \[[@CR16]\]GITR, IncHumanized mAb against GITR*CTLA-4* cytotoxic T-lymphocyte-associated antigen 4, *GITR* glucocorticoid-induced tumor necrosis factor receptor-related gene, *IgG* immunoglobulin G, *LAG-3* lymphocyte activation gene-3, *mAb* monoclonal antibody, *MHC* major histocompatibility complex, *PD-1* programmed death 1, *PD-L1* programmed death ligand 1, *PD-L2* programmed death ligand 2Table 2Preliminary efficacy data with immune checkpoint inhibitors or controls from individual (not head-to-head) trials^a^ \[[@CR4], [@CR5], [@CR7], [@CR17], [@CR18], [@CR21]--[@CR33]\]Advanced tumor settingAgent or controlMedian PFSMedian OSSurvival rateReference(s)MelanomaCTX (CTX-naïve pts)ND9.1--10.7 months1-year: 36 %\
3-year: 12--17 %\[[@CR5], [@CR21]\]Ipilimumab2.9 months10.1 months3-year: ≈20 %\[[@CR4]\]TremelimumabND12.6 months3-year: 21 %\[[@CR21]\]Pembrolizumab5.5 monthsNR1-year: 69 %\[[@CR7]\]Nivolumab3.7 months17.3 months1-year: 63 %\
3-year: 41 %\[[@CR22]\]Pidilizumab1.9 monthsND1-year: 65 %\[[@CR23]\]Nivolumab plus ipilimumab27 weeks40 months1-year: 85 %\
2-year: 79 %\[[@CR24]\]NSCLCCTX (CTX-naïve pts)4.2 months8.3 months1-year: 39 %\
2-year: 18 %\[[@CR18]\]Pembrolizumab10--27 weeks^b^51 weeksND\[[@CR25]--[@CR27]\]Nivolumab (previously-treated pts)2.3 months9.9 months1-year: 42 %\
3-year: 24 %\[[@CR28]\]Nivolumab (CTX-naïve pts)36.1 weeksNR1-year: 75 %\[[@CR29]\]RCCSorafenib3.6--5.7 months11.0--19.2 months3-year: ≈25 %\[[@CR30]--[@CR32]\]Nivolumab2.7--4.2^c^ months18.2--24.7^c^ months2.5-year: ≈35 %\[[@CR33]\]CRPCPlacebo3.1 months10.0 months1-year: 40 %\
2-year: 15 %\[[@CR17]\]Ipilimumab4.0 months11.2 months1-year: 47 %\
2-year: 26 %\[[@CR17]\]*CRPC* castration-resistant prostate cancer, *CTX* chemotherapy, *ND* no data, *NR* not reached, *NSCLC* non-small-cell lung cancer, *OS* overall survival, *PFS* progression-free survival, *pts* patients, *RCC* renal cell carcinoma^a^Important: data are not from head-to-head trials, and the trials differ by patient characteristics, patient numbers, and length of follow-up, therefore direct comparisons across trials and agents have limited validity; trials in tumor types with PFS and OS data were included^b^Based on differing studies and data-cuts^c^Dose-dependent

Ipilimumab was evaluated as adjuvant therapy following complete resection of stage III melanoma in a phase III trial in patients at high risk of recurrence \[[@CR34]\]. Patients receiving ipilimumab had a significantly increased median OS as compared with patients receiving placebo: 26.1 versus 17.1 months (*P* = 0.0013). The 3-year rates of recurrence-free survival were 47 % for ipilimumab and 35 % for placebo.

Preclinical studies suggest that chemotherapy can induce the release of tumor-specific antigens, thereby initiating T-cell activation and sensitizing tumor cells to T-cell-mediated killing \[[@CR35]\]. These observations provided the rationale for combining immunotherapy with cytotoxic agents to improve responses in patients with melanoma, and also led to the initiation of clinical trials evaluating ipilimumab with chemotherapy in lung cancer. A phase II, randomized study provided evidence that sequential ipilimumab is more effective than concurrent ipilimumab when administered with paclitaxel/carboplatin in chemotherapy-naïve stage IIIB/IV patients with non-small-cell lung cancer (NSCLC). The median OS with sequential ipilimumab, concurrent ipilimumab, and the control regimen was 12.2, 9.7, and 8.3 months, respectively. In this trial, patients with squamous histology exhibited better outcomes (median immune-related progression-free survival \[irPFS\] and OS) with sequential ipilimumab dosing than did patients with non-squamous histology \[[@CR18]\]. Based on these findings, a phase III trial evaluating OS in patients with squamous NSCLC receiving sequential ipilimumab after chemotherapy was initiated (Table [3](#Tab3){ref-type="table"} \[[@CR16]\]).Table 3Ongoing phase II and III clinical trials of immune checkpoint inhibitors \[[@CR16]\]^a^Target\
Treatment approach\
Tumor typeTrial phaseTreatment settingTrial stage (no. patients)Clinical endpointsEstimated primary/final completion dateTrial identifier**CTLA-4***Ipilimumab* ^b^Lung cancer Ipilimumab + etoposide/platinum vs. etoposide/platinumIIIExtensive-disease SCLCRecruiting (*n* = 1,100)Primary: OS\
Secondary: OS, irPFS, BORR, DORNov 2015/Mar 2017NCT01450761 Ipilimumab + paclitaxel/carboplatin vs. paclitaxel/carboplatinIIIStage IV/recurrent squamous NSCLCRecruiting (*n* = 920)Primary: OS\
Secondary: OS, PFS, BORRApr 2015/Dec 2016NCT01285609Melanoma IpilimumabI/IIUveal melanomaRecruiting (*n* = 141)Primary: MTD\
Secondary: OSNov 2017NCT01585194 Ipilimumab + temozolomideIIMetastatic melanomaOngoing (*n* = 64)Primary: 6-month PFSMay 2015NCT01119508 Ipilimumab vs. chemotherapy (retreatment)IIAdvanced melanoma with progression after initial disease control with ipilimumabOngoing (*n* = 138)Primary: OS\
Secondary: DCR, BORR, QOLJul 2016NCT01709162 Ipilimumab 3 mg/kg vs. 10 mg/kgIIIUnresectable or metastatic melanomaOngoing (*n* = 700)Primary: OS\
Secondary: PFS, BORR, DCR, DOR, DSDSep 2015/Dec 2016NCT01515189 Ipilimumab vs. placeboIIIHigh-risk stage III melanoma after surgical removalOngoing (*n* = 950)Primary: RFS\
Secondary: OS, distant metastases-free survival, safety, QOLJuly 2013/April 2015NCT00636168 Ipilimumab vs. nivolumab vs. ipilimumab + nivolumabIIIPreviously untreated advanced melanomaRecruiting (*n* = 915)Primary: OS\
Secondary: PFS, ORR, PD-L1 biomarker, QOLOct 2016/Oct 2017NCT01844505 Ipilimumab vs. high-dose IFN-α-2bIIIHigh-risk stage III or IV melanoma after surgical removalRecruiting (*n* = 1,500)Primary: Recurrence-free survival, OS\
Secondary: Safety, QOLMay 2018NCT01274338Prostate cancer Ipilimumab + sipuleucel-TIIProgressive metastatic prostate cancerOngoing (*n* = 66)Primary: Safety, immune responses\
Secondary: PSA response, clinical response, immune markersAug 2014/Aug 2015NCT01804465 Ipilimumab vs. placeboIIIMetastatic prostate cancerOngoing (*n* = 600)Primary: OS\
Secondary: PFS, time to pain progression, time to subsequent non-hormonal systemic therapy, safetyJan 2015/Nov 2015NCT01057810Gastric cancer Ipilimumab vs. standard of careIIUnresectable or metastatic gastric and gastroesophageal cancerRecruiting (*n* = 114)Primary: irPFS\
Secondary: PFS, OS, irBORRJul 2014/Mar 2015NCT01585987*Tremelimumab*Mesothelioma Tremelimumab vs. placeboIIUnresectable malignant mesotheliomaRecruiting (*n* = 180)Primary: OS\
Secondary: DCR, PFS, ORR, DOR, safety, QOL, PKJun 2015NCT01843374**PD-1***Pembrolizumab* (*MK-3475*)Lung cancer Pembrolizumab vs. docetaxelII/IIIPreviously treated PD-L1-positive NSCLCRecruiting (*n* = 920)Primary: OS, PFS, safety\
Secondary: ORR, DORSep 2015/Jan 2020NCT01905657Melanoma Pembrolizumab vs. chemotherapy^c^IIAdvanced melanoma with progression after prior therapyOngoing (*n* = 510)Primary: PFS, OS\
Secondary: ORR, DORMar 2015/Jan 2016NCT01704287 Pembrolizumab vs. ipilimumabIIIUnresectable or metastatic melanomaRecruiting (*n* = 645)Primary: PFS, OS\
Secondary: ORRJul 2014/Mar 2016NCT01866319Melanoma or NSCLC with untreated brain metastases PembrolizumabIIMelanoma or NSCLC with untreated brain metastasesRecruiting (*n* = 64)Primary: Response\
Secondary: Brain metastases responseDec 2018/Mar 2018NCT02085070Colon cancerPembrolizumabIIColon cancerRecruiting (*n* = 71)Primary: irPFS, irOR\
Secondary: OS, irPFS, PFS, BORR, DCR, safety, biomarkersJun 2017NCT01876511*Nivolumab*Lung cancer NivolumabIIAdvanced or metastatic squamous cell NSCLC with ≥2 prior systemic regimensOngoing (*n* = 100)Primary: IRC-assessed ORR\
Secondary: Investigator-assessed ORRFeb 2014/Feb 2015NCT01721759 Nivolumab + epigenetic primingIIRecurrent metastatic NSCLCRecruiting (*n* = 120)Primary: Tumor response\
Secondary: PFS, TTP, OS, safetyJan 2015/Aug 2015NCT01928576 Nivolumab vs. docetaxelIIIPreviously treated advanced or metastatic squamous cell NSCLCOngoing (*n* = 264)Primary: IRC-assessed ORR, OS\
Secondary: IRC-assessed PFS, PD-L1 biomarker, DOR, TTR, QOLAug 2014/Aug 2015NCT01642004 Nivolumab vs. docetaxelIIIPreviously treated advanced or metastatic non-squamous cell NSCLCOngoing (*n* = 574)Primary: OS\
Secondary: ORR, PFS, PD-L1 biomarker, DRSPRNov 2014/Nov 2015NCT01673867Melanoma Nivolumab + ipilimumab vs. ipilimumabIIPreviously untreated, unresectable or metastatic melanomaOngoing (*n* = 150)Primary: ORR\
Secondary: PFS, ORR and PFS in BRAF mutant patients, QOLJul 2014/May 2015NCT01927419 Nivolumab + ipilimumabIIAdvanced or metastatic melanomaRecruiting (*n* = 100)Primary: Safety\
Secondary: ORR, PRAug 2014/Jan 2019NCT01783938 Nivolumab vs. dacarbazine or carboplatin/paclitaxelIIIAdvanced melanoma with progression after ipilimumabOngoing (*n* = 390)Primary: ORR, OS\
Secondary: PFS, PD-L1 biomarker, QOLMay 2015/Jan 2016NCT01721746 Nivolumab vs. dacarbazineIIIPreviously untreated unresectable or metastatic melanomaRecruiting (*n* = 410)Primary: OS\
Secondary: PFS, ORR, PD-L1 biomarker, QOLSep 2015/Nov 2015NCT01721772 Nivolumab or nivolumab + ipilimumab vs. ipilimumabIIIPreviously untreated unresectable or metastatic melanomaRecruiting (*n* = 915)Primary: OS\
Secondary: PFS, ORR, PD-L1 biomarker, QOLOct 2016/Oct 2017NCT01844505RCC NivolumabIIAdvanced or metastatic clear-cell RCCOngoing (*n* = 150)Primary: PFS\
Secondary: PFS,\
BORR, OSMay 2013/Jun 2014NCT01354431 Nivolumab vs. everolimusIIIPre-treated advanced or metastatic clear-cell RCCRecruiting (*n* = 822)Primary: OS\
Secondary: PFS, ORR, DOR, PD-L1 biomarker, safety, DRSPRFeb 2016NCT01668784Other Nivolumab or nivolumab + ipilimumab vs. bevacizumabIIRecurrent glioblastomaRecruiting (*n* = 260)Primary: Safety, OS\
Secondary: PFS, ORR, OSJan 2018NCT02017717 NivolumabIIRelapsed or refractory diffuse large B-cell lymphomaRecruiting (*n* = 120)Primary: ORR\
Secondary: DOR, CRR, PFS, ORRFeb 2016NCT02038933 NivolumabIIIRecurrent or metastatic head and neck carcinomaRecruiting (*n* = 180)Primary: PFS, OS\
Secondary: ORRJun 2016/Jun 2017NCT02105636*Pidilizumab* (*CT-011*)Prostate cancer Pidilizumab + sipuleucel-T + cyclophosphamideIIAdvanced prostate cancerRecruiting (*n* = 57)Primary: Feasibility, immune efficacy\
Secondary: PFS, OSDec 2014/Dec 2017NCT01420965Hematologic malignancies Pidilizumab + vaccineIIAMLRecruiting (*n* = 75)Primary: Toxicity\
Secondary: Immune response, tumor regression, TTPSep 2014NCT01096602 Pidilizumab + lenalidomideIIRelapsed or refractory MMRecruiting (*n* = 53)Primary: MTD, OR,\
Secondary: TTP, OS, PKJun 2017NCT02077959**PD-L1***MPDL3280A*Lung cancer MPDL3280AIIPD-L1-positive locally advanced or metastatic NSCLCRecruiting (*n* = 130)Primary: ORR\
Secondary: ORR, DOR, PFS, safety, PKMay 2015NCT01846416 MPDL3280A vs. docetaxelIIAdvanced or metastatic NSCLC after platinum failureRecruiting (*n* = 300)Primary: OS\
Secondary: OR, PFS, safety, QOLMar 2016/Mar 2017NCT01903993 MPDL3280AIIPD-L1-positive advanced or metastatic NSCLCRecruiting (*n* = 300)Primary: ORR\
Secondary: DOR, PFS, OS, safety, PKMar 2018NCT02031458 MPDL3280A vs. docetaxelIIIAdvanced or metastatic NSCLC after platinum failureRecruiting (*n* = 850)Primary: OS\
Secondary: Safety, OR, PFS, DORJun 2018NCT02008227Other MPDL3280A or MPDL3280A + bevacizumab vs. sunitinibIIPreviously untreated locally advanced or metastatic RCCRecruiting (*n* = 150)Primary: PFS\
Secondary: irPFS, OR, DOR, OS, PKMar 2016NCT01984242 MPDL3280AIILocally advanced or metastatic urothelial bladder cancerRecruiting (*n* = 330)Primary: ORR\
Secondary: DOR, PFS, OS, safety, PKNov 2015/Jul 2016NCT02108652*MEDI4736*Lung cancer MEDI4736IILocally advanced or metastatic NSCLC with ≥2 prior systemic regimensRecruiting (*n* = 210)Primary: ORR\
Secondary: DOR, PFS, DCR, OS, DSR, safety, PKApr 2015/Jan 2016NCT02087423 MEDI4736 vs. docetaxel (sub-study)IIAdvanced squamous NSCLCRecruiting (*n* = undefined for substudy)Primary: PFS, OS\
Secondary: ORR, safety, irPFS, irORJun 2022NCT02154490 MEDI4736 vs. placebo following concurrent chemoradiationIIIStage III unresectable NSCLCRecruiting (*n* = 880)Primary: OS, PFS\
Secondary: OS, DOR, ORR, PFSMay 2017/Nov 2020NCT02125461*AML* acute myelogenous leukemia, *BORR* best overall response rate, *CRR* complete remission rate, *CTLA-4* cytotoxic T-lymphocyte-associated antigen 4, *DCR* disease control rate, *DMFS* distant metastases-free survival, *DOR* duration of response, *DRSPR* disease-related symptom progression rate, *DSD* duration of stable disease, *DSR* deep sustained response, *IFN* interferon, *irBORR* immune-related best overall response rate, *IRC* independent review committee, *irOR* objective response using immune-related response criteria, *irPFS* immune-related progression free survival, *MM* multiple myeloma, *MTD* maximum tolerated dose, *NSCLC* non-small-cell lung cancer, *OR* overall response, *ORR* objective response rate, *OS* overall survival, *PD-1* programmed death-1, *PD-L1* programmed death ligand 1, *PFS* progression-free survival, *PK* pharmacokinetics, *PR* progression rate, *PSA* prostate specific antigen, *QOL* quality of life, *RCC* renal cell carcinoma, RFS recurrence-free survival, *SCLC* small cell lung cancer, *TTP* time to progression, *TTR* time to response^a^Active (as of July 2014) phase II and III trials with planned enrolment of ≥50 patients are listed^b^Due to the high volume of ipilimumab trials, only those with Bristol-Myers Squibb listed as the sponsor or collaborator are included^c^Investigator-choice chemotherapy (carboplatin + paclitaxel, paclitaxel alone, dacarbazine, or temozolomide)

Ipilimumab is also being investigated in the setting of metastatic castration-resistant prostate cancer (mCRPC). In a phase III trial of ipilimumab versus placebo in post-docetaxel patients with mCRPC receiving a single dose of radiotherapy, the primary endpoint of OS was not reached; however, pre-specified subset analyses suggested that ipilimumab may be more active in patients with favorable prognostic factors, including no visceral disease, alkaline phosphatase \<1.5 upper limit of normal, and hemoglobin ≥11 g/dL \[[@CR17]\]. Results from this study support the investigation of ipilimumab in the ongoing phase III, CA184-095 study among chemotherapy-naïve patients with mCRPC (Table [3](#Tab3){ref-type="table"} \[[@CR16]\]).

### Tremelimumab {#Sec6}

Tremelimumab is a fully human immunoglobulin G (IgG)-2 monoclonal antibody targeting CTLA-4 \[[@CR6]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). Tremelimumab provided durable responses in 6.6 % of patients in a phase II trial of patients with advanced melanoma, as compared with the objective response rates (ORRs) of 5.7 and 10.9 % seen in the phase III trial of ipilimumab with or without vaccine \[[@CR4], [@CR6]\]. However, the phase III trial of tremelimumab monotherapy failed to demonstrate a statistically significant survival advantage over chemotherapy in first-line treatment of patients with metastatic melanoma \[[@CR21]\]. Patient selection criteria, dosing regimen, and use of ipilimumab as salvage therapy for patients in the control arm were potential reasons for the lack of survival benefit.

Tremelimumab showed evidence of activity against previously treated malignant mesothelioma in a small (*N* = 29) phase II single-arm trial \[[@CR36]\]. Four patients had partial responses, and 11 patients had stable disease of median duration 7.7 months (range 2.6--16.6+), with a median OS of 11.3 months. Based on these results, a phase II trial of tremelimumab in malignant mesothelioma has been initiated (Table [3](#Tab3){ref-type="table"} \[[@CR16]\]).

Safety of CTLA-4 Inhibitors {#Sec7}
---------------------------

The cumulative safety data across many trials show that agents that inhibit CTLA-4 are generally safe, with unique, but usually manageable, side effects that are linked to their mechanism of stimulating immune responses. Multiple phase II and III trials have characterized these immune-related adverse events (irAEs) of CTLA-4 inhibition. Overall, irAEs were observed in 58--63 % of patients treated with ipilimumab, with 5--26 % of patients experiencing grade 3/4 irAEs \[[@CR4], [@CR17], [@CR37]\] (Table [4](#Tab4){ref-type="table"} \[[@CR4], [@CR7], [@CR8], [@CR12]--[@CR14], [@CR17], [@CR21], [@CR23], [@CR26], [@CR28], [@CR36], [@CR38]--[@CR40]\]). In the phase III trial investigating ipilimumab treatment with or without vaccine, skin-related irAEs (including pruritus, rash, and erythema) and gastrointestinal irAEs (including diarrhea and colitis) were the most common, occurring in 29--44 % of patients; endocrine disorders were reported in 4--8 % of patients \[[@CR4]\]. Some of the more rare adverse events (AEs) (≤1 % for each) reported during treatment with ipilimumab include uveitis, conjunctivitis, and neuropathy \[[@CR37]\]. Interestingly, when ipilimumab was given with dacarbazine, immune-mediated grade 3/4 hepatitis occurred in 32 % of patients, while the rates of gastrointestinal events, such as colitis, were lower than expected based on previous trials \[[@CR5]\]. As adjuvant therapy, ipilimumab had a safety profile generally consistent with that seen in patients with advanced melanoma, although the incidence of some irAEs (e.g. endocrinopathies) was higher. Also, five patients (1 %) in the ipilimumab arm died due to treatment-related AEs versus 0 patients in the placebo group \[[@CR34]\]. Tremelimumab has a similar irAE profile to ipilimumab. The most common irAEs with tremelimumab were gastrointestinal (18 % grade 3--5), dermatologic (rash 33 % all grades, 2 % grade 3--5), and endocrine (thyroid/panhypopituitarism/adrenal insufficiency 7 %) in nature \[[@CR21]\] (Table [4](#Tab4){ref-type="table"} \[[@CR4], [@CR7], [@CR8], [@CR12]--[@CR14], [@CR17], [@CR21], [@CR23], [@CR26], [@CR28], [@CR36], [@CR38]--[@CR40]\]).Table 4Preliminary safety data of CTLA-4, PD-1, and PD-L1 targeting agents^a^ \[[@CR4], [@CR7], [@CR8], [@CR12]--[@CR14], [@CR17], [@CR21], [@CR23], [@CR26], [@CR28], [@CR36], [@CR38]--[@CR40]\]Agent nameSettingPhaseDosing/descriptionPatients (*N*)Treatment-related AEsGrade 3/4 treatment-related AEsPotential immune-related AEs^b^**Anti-CTLA-4 agents** Ipilimumab \[[@CR4]\]Unresectable stage III or IV melanomaIII3 mg/kg q3w, for up to 4 doses13180 % (*n* = 105), including fatigue 42 %, nausea 35 %, diarrhea 33 %, decreased appetite 27 %, vomiting 24 %, constipation 21 %; 4 TRDGrade 3: 19 % (*n* = 25), including fatigue 7 %, diarrhea 5 %, dyspnea 3 %, anemia 3 %\
Grade 4: 4 % (*n* = 5), including dyspnea 1 %Any grade: 61 % (*n* = 80), including diarrhea 28 %, pruritus 24 %, rash 19 %, colitis 8 %, endocrine disorders 8 %\
Grade 3: 12 % (*n* = 16), including diarrhea 5 %, colitis 5 %, endocrine disorders 2 %\
Grade 4: 2 % (*n* = 3) Ipilimumab \[[@CR17]\]mCRPC with bone metastasisIII10 mg/kg q3w, for up to 4 doses, after radiotherapy39375 % (*n* = 295); 4 TRDNDAny grade: 63 % (*n* = 249)\
Grade 3/4: 26 % (*n* = 101) Tremelimumab \[[@CR21]\]Treatment-naïve, unresectable stage IIIc or IV melanomaIII15 mg/kg once q90d325All cause^c^: 96 % (*n* = 312), including diarrhea 51 %, nausea 34 %, fatigue 33 %, rash 33 %, pruritus 31 %, vomiting 23 %, decreased appetite 21 %; 7 TRDAll cause^b^:\
52 % (*n* = 170), including diarrhea 18 %, fatigue 6 %, nausea 4 %, vomiting 4 %, decreased appetite 4 %, abdominal pain 4 %Any grade AEs included thyroid disorders 5 %, ocular disorders 4 %, hypothalamus and pituitary disorders 2 %\
Grade 3/4:\
1 % each for thyroid disorders, hypothalamus and pituitary disorders, adrenal insufficiency, hepatitis, pancreatitis Tremelimumab \[[@CR36]\]CTX-resistant advanced malignant mesotheliomaII10 mg/kg once q90d29Grade 1/2: 90 % (*n* = 26), including GI AEs 66 %, dermatologic AEs 48 %, fever 34 %3 % (*n* = 1)None reported^d^**Anti-PD-1 agents** Pembrolizumab \[[@CR7]\]Advanced melanomaI10 mg/kg q2/3w, or 2 mg/kg q3w41183 % (*n* = 341), including fatigue 36 %, pruritus 24 %, rash 20 %, diarrhea 16 %, arthralgia 16 %, nausea 12 %, vitiligo 11 %12 % (*n* = 51), including fatigue 2 %; all others \<1 %Any grade hypothyroidism 8 %, pneumonitis 3 %, hyperthyroidism 1%, colitis \<1 %, hepatitis \<1 %\
Individual grade 3--4 events each occurred in \<1 % Pembrolizumab \[[@CR26]\]NSCLC previously treated with ≥1 systemic regimensI10 mg/kg q2/3w21764 %, including fatigue 20 %, arthralgia 9 %, decreased appetite 9 %, pruritus 8 %, diarrhea 7 %10 %, including fatigue, arthralgia, nausea, each \<1 %Any grade rash 6 % and hypothyroidism 5 %\
Grade 3--4 pneumonitis: 2 % (*n* = 4)\
Grade 3--4 arthralgia, neck pain, pneumonitis 2 % (*n* = 4) Nivolumab \[[@CR8]\]Advanced or recurrent malignanciesI0.1--10 mg/kg every 2 weeks, maximum of 12 cycles (4 doses per 8-week cycle)29670 % (*n* = 207), including fatigue 24 %, nausea 8 %, decreased appetite 8 %14 % (*n* = 41), including fatigue 2 %, abdominal pain 1 %, hypophosphatemia 1 %, lymphopenia 1 %All grades: 41 % (*n* = 122), including rash 12 %, diarrhea 11 %, pruritus 9 %, pneumonitis 3 %, vitiligo 3 %, infusion-related AEs 3 %, increased TSH 3 %\
Grade 3/4: 6 % (*n* = 18), including pneumonitis 1 %, diarrhea 1 %, increased AST 1 %, increased ALT 1 %, 3 deaths from pneumonitis 1 % Nivolumab \[[@CR28]\]Advanced NSCLC (subset analysis)I1--10 mg/kg q2w maximum of 12 cycles (4 doses per 8-week cycle)129ND, including fatigue 24 %, decreased appetite 12 %, diarrhea 10 %14 %All grades: 41 % (*n* = 53) including skin 16 %, GI 12 %, pulmonary 7 %, endocrinopathies 6 %\
Grade 3/4: 5 % (*n* = 6), including pneumonitis, 3 % (*n* = 4), GI, hepatic, and infusion reaction 1 %, (*n* = 1, each); 3 deaths from pneumonitis Nivolumab \[[@CR38]\]Advanced melanoma (subset analysis)I1--10 mg/kg q2w for a maximum of 12 cycles (4 doses per 8-week cycle)10784 % (*n* = 90), including fatigue 32 %, rash 23 %, diarrhea 18 %22 %, including lymphopenia 3 %, fatigue 2 %, diarrhea 2 %, abdominal pain 2 %Any grade: 54 % (*n* = 58), including skin 36 %, GI 18 %, endocrinopathies 13 %, hepatic 7 %, infusion reaction 6 %, pulmonary 4 %, and renal 2 %\
Grade 3/4: 5 % (*n* = 5), including GI and endocrinopathies 2 % each, and hepatic and renal 1 % each Nivolumab \[[@CR33]\]mRCCII0.3, 2.0, or 10 mg/kg q3w16867--78 %^e^, including fatigue 22--35 %, hypersensitivity 0--17 %, diarrhea 3--15 %, arthralgia 2--15 %, nausea 10--13%, rash 7--13%, pruritus 9--11%5--17 %^e^, including nausea, pruritus, arthralgia 0--2 % eachAny grade^e^: skin 22--28 %, hypersensitivity/infusion reaction 4--19 %, GI 5--15 %, endocrine 5--11 %, hepatic 3--7 %, pulmonary 4--7 %, renal 0--2 %\
Grade 3/4^e^: skin 0--4 %, endocrine 0--4 %, hepatic 0--4 %, GI 0--2 % Pidilizumab \[[@CR23]\]Stage IV progressing melanomaII1.5 or 6.0 mg/kg q2w up to 54 weeks10768 %, including fatigue 31 %, diarrhea 16 %, arthralgia 13 %, anemia 11 %, nausea 10 %, hyperglycemia 2 %4 %, including arthralgia 1 %, anemia 2 %Grade 3 appendicitis, grade 3 arthritis, grade 4 hepatitis and grade 3 pneumonitis 1 % each**Anti-PD-L1 agents** MPDL3280A \[[@CR39]\]Locally advanced or metastatic NSCLC (subset analysis)IDose escalation, 1--20 mg/kg q3w up to 1 year8566 % (*n* = 56), including fatigue 20 %, nausea 14 %, decreased appetite 12 %, dyspnea 9 %, diarrhea 8 %11 % (*n* = 9), including fatigue 2 %, nausea 1 %, dyspnea 1 %, vomiting 1 %1 case of grade 3/4 diabetes mellitus 1 % MPDL3280A \[[@CR12]\]Metastatic urothelial bladder cancerI15 mg/kg q3w up to 1 year6857 % (*n* = 39), including decreased appetite 12 %, fatigue 12 %, nausea 12 %, pyrexia 9 %, asthenia 7 %4 % (*n* = 3), including asthenia 2 %No cases were reported BMS-936559 \[[@CR13]\]Advanced or recurrent solid tumorsIDose escalation, 0.3--10 mg/kg q2w in 6-week cycles up to 16 cycles20761 % (*n* = 126), including fatigue 16 %, infusion reactions 10 %, rash 9 %, diarrhea 9 %, arthralgia 7 %9 % (*n* = 19), including fatigue 1 %, infusion-related AEs 1 %, lymphopenia 1 %39 % (*n* = 81), including rash 7 %, hypothyroidism 3 %, hepatitis 1 %, one case each of sarcoidosis, endophthalmitis, diabetes mellitus, myasthenia gravis\
Grade 3/4: 5 % (*n* = 10), including infusion reaction \<1 %, adrenal insufficiency \<1 % MEDI4736 \[[@CR14]\]Advanced solid tumorsI10 mg/kg q2w up to 1 year34639 % (*n* = 135), including fatigue 13 %, rash/pruritus 9 %, vomiting 5 %, diarrhea 5 %6 % (*n* = 20), including fatigue 1 %, elevated AST/ALT 1 %, vomiting, hypothyroidism, hyperglycemia, rash/pruritus, all \<1 %All grades: elevated AST/ALT 4 %, hypothyroidism 2 %, hyperthyroidism 1 %, pneumonitis 1 %, peripheral neuropathy 1 %*AE* adverse event, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *CTLA-4* cytotoxic T-lymphocyte-associated antigen 4, *CTX* chemotherapy, *GI* gastrointestinal, *mCRPC* metastatic castration-resistant prostate cancer, *mRCC* metastatic renal cell carcinoma, *ND* no data, *NSCLC* non-small cell lung cancer, *PD-1* programmed death-1, *PD-L1* programmed death ligand 1, *qxd* every x days, *qxw* every x weeks, *TRD* treatment-related deaths, *TSH* thyroid stimulating hormone^a^Monotherapy trials in solid tumors were included^b^As determined by the investigator^c^Treatment-related AEs not available^d^At 15 mg/kg the following immune-related AEs were reported: Grade 3 colitis or diarrhea: 7 % (*n* = 2); Grade 3 Guillain-Barré-like peripheral neuropathy: 3 % (*n* = 1); Grade 4 increases in transaminases and pancreatic enzymes: 3 % (*n* = 1) \[[@CR40]\]^e^Depending on dose

irAEs for CTLA-4 inhibitors tend to occur during the induction period or first 12 weeks of therapy, but, in rare cases, can occur in the weeks and even months following discontinuation of therapy \[[@CR37]\]. Grade 2 irAEs are usually responsive to interruption of therapy and institution of low-dose steroids (0.5 mg/kg/day of prednisone), and grade 3 and higher irAEs are generally responsive to high-dose steroids (1--2 mg/kg/day of prednisone or equivalent), although the steroid-refractory patients (reported as 2--8 % of patients) \[[@CR20], [@CR41]\] may require the use of alternate immunosuppressive agents, such as infliximab (5 mg/kg) once every 2 weeks until symptom resolution, followed by a prolonged steroid taper \[[@CR42]\]. Prompt recognition, management, and monitoring of grade 2 and higher irAEs are critical for the successful resolution of these toxicities, although such events can often take weeks to months to return to baseline. Algorithms for the management of irAEs with ipilimumab have been published by Fecher et al. \[[@CR37]\]. Unfortunately, prophylactic steroids and other preventive strategies to avoid irAEs have not shown clinical benefit to date \[[@CR37]\]. An interesting and consistent observation is that a higher incidence of irAEs, particularly grade 3/4 irAEs, has been associated with a higher proportion of patients eventually achieving an objective response \[[@CR43]\]. However, as grade 3/4 irAEs can be life threatening, it is recommended that patients experiencing severe irAEs discontinue ipilimumab \[[@CR20], [@CR37]\].

Programmed Death-1 (PD-1) and Programmed Death Ligand 1 (PD-L1) {#Sec8}
===============================================================

Background {#Sec9}
----------

PD-1 (CD279) is also a co-inhibitory molecule that plays an important role in the balance of tumor immunity and inflammatory reactions \[[@CR3], [@CR44]\]. However, in contrast to CTLA-4, PD-1 appears to play a greater role in limiting and modulating the activity of T cells in peripheral tissues and organs during inflammatory responses in an effort to prevent host tissue damage. PD-1 expression is induced on activated T cells, and the interaction between PD-1 and one of its ligands---typically PD-L1 (B7-H1, CD274) or PD-L2 (B7-DC, CD273)---on the surface of tumors leads to a diminished antitumor response and has been associated with a poorer patient outcome \[[@CR44]\]. High levels of PD-1 expression on antigen-experienced CD8^+^ T cells are associated with the loss of effector functions, including the ability of T cells to proliferate and express interleukin (IL)-2, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ---a process termed T-cell 'exhaustion' or 'tolerance'. In this state, tumor-infiltrating lymphocytes become tolerant and are less capable of carrying out antitumor immune responses as a result of chronic antigen exposure and prolonged negative immune regulation. While both CTLA-4 and PD-1 are immune checkpoint inhibitors, CTLA-4 is thought to act earlier in the process of T-cell activation, whereas PD-1 plays a role in attenuating T-cell responses later in the process, after T cells have migrated to the tumor microenvironment \[[@CR44]\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Inhibiting the CTLA-4 and PD-1 immune checkpoint pathways to restore antitumor immune responses. In peripheral lymphoid organs and tissues, anti-CTLA-4 antibodies block CTLA-4 from binding CD80/86 on APCs and prevent T-cell inhibition. In the tumor microenvironment, PD-L1 and/or PD-L2 expression inhibits PD-1-expressing T cells. Interruption of PD-1:PD-L1 and PD-1:PD-L2 binding by anti-PD-1 antibodies or interruption of PD-1:PD-L1 binding by anti-PD-L1 antibodies restores T-cell immune responses. *APC* antigen-presenting cell, *CTLA-4* cytotoxic T-lymphocyte-associated antigen 4, *MHC* major histocompatibility complex, *PD-1* programmed death-1, *PD-L1* programmed death ligand 1, *PD-L2* programmed death ligand 2, *TCR* T-cell receptor

Given these observations, both PD-1 and PD-L1 antibody blockade may be a promising target for cancer immunotherapy (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR3], [@CR45]\]. Anti-PD-1 antibodies are designed to inhibit PD-1 from engaging with any of its ligands, thereby preventing both PD-1:PD-L1 and PD-1:PD-L2 binding. In contrast, anti-PD-L1 agents prevent PD-1:PD-L1 binding, but not necessarily PD-1:PD-L2 binding. There is evidence that PD-L1 may bind CD80 (B7-1) on T cells, leading to a down-regulatory signal; hence, anti-PD-L1 could inhibit this interaction as well \[[@CR3], [@CR44]\]. Given the current understanding that PD-1:PD-L1 interactions are a predominant mechanism of tumor immune evasion, whether agents targeting PD-1 versus PD-L1 will have different clinical profiles is unknown.

To date, all data reported for PD-1 pathway inhibitors have been in phase I or II studies without control arms. The ongoing phase II and III trials that include control arms should provide data with greater context. Table [2](#Tab2){ref-type="table"} lists PFS and OS data from historical controls and studies where these data were available. However, as the studies differ greatly in terms of patient characteristics, study sizes, and length of follow-up, direct comparisons should be made with great caution.

Efficacy with PD-1 Inhibitors {#Sec10}
-----------------------------

### Pembrolizumab (MK-3475) {#Sec11}

Pembrolizumab (MK-3475) is a humanized IgG4 monoclonal antibody against PD-1 \[[@CR7]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). A phase I study, including expansion cohorts, evaluated pembrolizumab treatment in patients with advanced melanoma who had previously received or not received ipilimumab \[[@CR7]\]. The overall response rate across all doses was 34 %; 88 % of responses were ongoing at the time of analysis and the median duration of response had not been reached. Prior treatment with immunotherapy, including ipilimumab and IL-2, did not preclude activity of pembrolizumab, nor were higher rates of AEs observed in patients who had received previous immunotherapy compared with those who had not. Preliminary survival data of pembrolizumab and other PD-1 pathway agents is listed in Table [2](#Tab2){ref-type="table"} \[[@CR4], [@CR5], [@CR7], [@CR18], [@CR19], [@CR21]--[@CR33]\].

Pembrolizumab was also investigated in a phase I study in patients with previously treated NSCLC \[[@CR25], [@CR26]\]. Interim data analysis revealed that, in a cohort of 217 patients with NSCLC, the ORR was 18 % based on immune-related response criteria (irRC), and the median OS was 51 weeks. irRC have been used primarily to assess responses in patients with melanoma, and have not been validated in other cancers \[[@CR46]\]. Responses were seen in patients with non-squamous and squamous histology, and in current/former and never smokers. \[[@CR25], [@CR26]\]. As a first-line therapy for NSCLC, pembrolizumab reported preliminary ORRs of 47 % by irRC. Median PFS was 27 weeks (Response Evaluation Criteria in Solid Tumors \[RECIST\]) and 37 weeks (irRC) \[[@CR27]\].

Pembrolizumab also showed antitumor activity in patients with head and neck cancer in a phase I study \[[@CR47]\]. Responses were seen in 20 % (11/56) of evaluable patients, which included human papillomavirus-positive and -negative tumors (Table [3](#Tab3){ref-type="table"} \[[@CR16]\]).

### Nivolumab {#Sec12}

Nivolumab (BMS-936558) is a fully human IgG4 PD-1 immune checkpoint inhibitor \[[@CR8]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). A phase I, dose-escalating study in multiple tumor types reported objective responses with nivolumab in a substantial portion of patients with melanoma, NSCLC, or renal cell carcinoma (RCC), but no objective responses in patients with colorectal cancer (CRC) or CRPC \[[@CR8]\]. In patients with melanoma treated with nivolumab across all doses in the phase I trial, the ORR was 32 % and the median duration of response was 99 weeks. The median OS was 17.3 months and 1-, 2-, and 3-year survival rates were 63, 48, and 41 %, respectively \[[@CR22]\] (Table [2](#Tab2){ref-type="table"} \[[@CR4], [@CR5], [@CR7], [@CR18], [@CR19], [@CR21]--[@CR33]\]).

In the phase I trial among patients with NSCLC and across all doses, the ORR was 17 % (22/129), the estimated median response duration was 74 weeks, and overall 1- and 2-year survival rates were 42 and 24 %, respectively \[[@CR28]\]. Ongoing trials are evaluating nivolumab alone or in combination with chemotherapy, erlotinib, or ipilimumab in patients with chemotherapy-naïve NSCLC, and have reported initial evidence of antitumor activity \[[@CR29], [@CR48]--[@CR50]\]. With first-line nivolumab monotherapy in a phase I trial, the initial ORR was 30 %, median PFS was 36.1 weeks, and median OS was not reached (range 13.3--89.1+) in 20 evaluable patients. The 1-year OS rate was 75 % \[[@CR29]\].

In phase II study in patients with previously-treated RCC, the overall response rate was 21 % (35/168), with the majority of responses lasting \>1 year \[[@CR33]\]. Across the evaluated doses, the PFS ranged from 2.7 to 4.2 months, and the median OS ranged from 18.2 to 24.7 months. The survival rate was approximately 35 % at 2.5 years \[[@CR33]\] (Table [2](#Tab2){ref-type="table"} \[[@CR4], [@CR5], [@CR7], [@CR18], [@CR19], [@CR21]--[@CR33]\]). Phase II and III trials of nivolumab are ongoing in melanoma, NSCLC, RCC, and squamous head and neck cancer (Table [3](#Tab3){ref-type="table"} \[[@CR16]\]).

### Pidilizumab (CT-011) {#Sec13}

Pidilizumab (CT-011) is a humanized anti-PD-1 IgG1 monoclonal antibody \[[@CR9]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). Pidilizumab was evaluated in patients with stage IV melanoma in a phase II open-label study. The ORR using irRC was 6 %, the median PFS was 1.9 months, and the 1-year survival rate was 65 % \[[@CR23]\] (Table [2](#Tab2){ref-type="table"} \[[@CR4], [@CR5], [@CR7], [@CR18], [@CR19], [@CR21]--[@CR33]\]).

Pidilizumab has also shown evidence of efficacy in patients with hematologic malignancies \[[@CR51]\]. Separately, pidilizumab after autologous hematopoietic stem-cell transplantation (AHSCT) was evaluated in a phase II trial in patients with diffuse large B-cell lymphoma (DLBCL) or primary mediastinal large B-cell lymphoma \[[@CR9]\]. A total of 66 patients completed all treatment cycles, and PFS at 16 months from the start of treatment was 72 %. This compares favorably with the PFS rate at 18 months of 52 % in a historical group of patients with DLBCL with similar characteristics (i.e., would have met the eligibility criteria for the study, including no progression or relapse within 2 months of AHSCT) who had received high-dose chemotherapy followed by AHSCT \[[@CR9], [@CR52]\]. Among the 35 patients with measurable disease after transplant, the overall response rate with pidilizumab treatment was 51 %, and the complete remission rate was 34 % \[[@CR9]\].

### AMP-224 {#Sec14}

AMP-224 is a recombinant fusion protein comprising the extracellular domain of PD-L2 and the Fc region of human IgG \[[@CR10]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). This agent is designed to bind PD-1, and preclinical studies suggest its mechanism of action may differ from monoclonal antibody blockade. A phase I trial evaluating the safety of AMP-224 in patients with advanced cancer is ongoing (NCT01352884) \[[@CR53]\]. Infusion reactions were common, occurring in 69 % of patients across dose cohorts. It is unclear whether this study is moving forward, as a high rate of infusion reactions and lack of efficacy have been observed compared with other PD-1 inhibitors.

Safety of PD-1 Inhibitors {#Sec15}
-------------------------

While no head-to-head trials have been conducted, the safety profiles of the anti-PD-1 agents seem to be generally similar. In the largest and most mature studies of pembrolizumab and nivolumab, grade 3/4 treatment-related AEs were reported in 10--22 % of patients \[[@CR7], [@CR8], [@CR26], [@CR38]\]. The most common treatment-related AE was fatigue in all studies (20--36 % all grades, 2 % grade 3/4). Potential immune-related select AEs were also commonly reported: dermatologic toxicities (pruritus ≤24 % all grades, \<1 % grade 3/4; rash 6--20 % all grades, \<1 % grade 3/4; vitiligo ≤11 % all grades, 0 % grade 3/4), gastrointestinal toxicities (diarrhea 7--16 % all grades, ≤1 % grade 3/4; nausea 6--12 % all grades, \<1 % grade 3/4), and endocrinopathies (hypothyroidism 2--8 % all grades, \<1 % grade 3/4; hyperthyroidism 1--2 % all grades, \<1 % grade 3/4). Arthralgia (all grades) was reported in 4--16 % of patients, and grade 3/4 in \<1 %. Pneumonitis of all grades was noted in 3 % of pembrolizumab- or nivolumab-treated patients, with ≤1 % of patients developing grade 3/4 pneumonitis. Although rare, three deaths due to pneumonitis in nivolumab-treated patients are concerning. Nivolumab or pembrolizumab in patients who had received prior ipilimumab showed similar safety profiles to those of ipilimumab-naïve patients, supporting the sequential use of these therapies \[[@CR54], [@CR55]\].

Efficacy with PD-L1 Inhibitors {#Sec16}
------------------------------

### MPDL3280A {#Sec17}

MPDL3280A is a human anti-PD-L1 monoclonal antibody \[[@CR11], [@CR12]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). MPDL3280A is being assessed in a dose-ranging phase I study in patients with multiple tumor types. Interim results from 53 evaluable patients with NSCLC revealed an ORR of 23 % in patients across squamous and non-squamous histologies, including several patients with rapid tumor shrinkage \[[@CR39]\]. Some patients (not included in the ORR) had delayed responses after apparent radiographic progression. Most responses were ongoing at the time of analysis. The ORR in patients with RCC was 13 %; durable responses were seen in patients with clear cell and non-clear cell disease \[[@CR11]\]. In patients with urothelial bladder cancer, the ORR was 25 % (17/67) \[[@CR12]\]. Phase II and III trials evaluating MPDL3280A in advanced lung cancer, advanced RCC, and urothelial bladder cancer are ongoing (Table [3](#Tab3){ref-type="table"} \[[@CR16]\]).

### BMS-936559 {#Sec18}

BMS-936559 is a fully human IgG4 monoclonal antibody directed against PD-L1 \[[@CR13]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). The safety and activity of BMS-936559 was assessed in a phase I dose-escalating study in patients with advanced solid tumors \[[@CR13]\]. Clinical activity was observed in patients with melanoma, NSCLC, RCC, CRC, ovarian, or pancreatic cancer, but not for patients with gastric or breast cancer. ORRs for patients with melanoma, NSCLC, RCC, and ovarian cancer were 17, 10, 12, and 6 %, respectively, and responses lasted for ≥1 year in 8 of 16 patients with at least 1 year of follow-up. No additional trials of BMS-936559 are currently listed in ClinicalTrials.gov \[[@CR16]\].

### MEDI4736 {#Sec19}

MEDI4736 is a human IgG1 monoclonal antibody that binds PD-L1 \[[@CR14]\] (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]). MEDI4736 is being investigated in multiple tumor types, including melanoma, NSCLC, squamous head and neck cancer, and pancreatic cancer in a phase I trial. A preliminary analysis reported ORRs of 13 % (6/47) in patients with NSCLC and 14 % (3/22) in patients with squamous head and neck cancer, and evidence of activity against pancreatic and gastroesophageal cancer \[[@CR14]\]. Numerous studies of MEDI4736 are planned or ongoing in patients with NSCLC or other malignancies (Table [3](#Tab3){ref-type="table"} \[[@CR16]\]).

Safety of PD-L1 Inhibitors {#Sec20}
--------------------------

The types of AEs reported with PD-L1 agents seem similar to those targeting PD-1, but the incidence of AEs appears to be lower. The reported rate of grade 3/4 treatment-related AEs across studies and tumor types ranged from 4 to 13 % \[[@CR11]--[@CR14], [@CR39]\]. Fatigue (12--20 % all grades, 0--2 % grade 3/4), gastrointestinal AEs (diarrhea 5--9 % all grades, 0 % grade 3/4; nausea 6--14 % all grades, 0--1 % grade 3/4), dermatologic AEs (rash 7--9 % all grades, \<1 % grade 3/4; pruritus 6 % all grades, \<1 % grade 3/4), and endocrinopathies (hypothyroidism 2--3 % all grades, \<1 % grade 3/4) were the most common.

BMS-936559 had a higher reported rate of infusion-related reactions (10 % all grades, ≤1 % grade 3/4) and arthralgia (7 % all grades, 0 % grade 3/4) than other PD-L1-targeting agents \[[@CR13]\] (Table [4](#Tab4){ref-type="table"} \[[@CR4], [@CR7], [@CR8], [@CR12]--[@CR14], [@CR17], [@CR21], [@CR23], [@CR26], [@CR28], [@CR36], [@CR38]--[@CR40]\]).

PD-L1 as a Predictive Biomarker {#Sec21}
-------------------------------

Emerging evidence suggests that PD-L1 expression on pre-treatment tumor specimens may be a predictive biomarker of efficacy with PD-1 pathway inhibitors. Across agents, studies, and tumor types, antitumor activity was generally higher against PD-L1-positive tumors versus tumors with low or negative staining for PD-L1 (Table [5](#Tab5){ref-type="table"} \[[@CR11], [@CR12], [@CR14], [@CR22], [@CR28], [@CR29], [@CR39], [@CR56]--[@CR59]\]). However, the methodology, amount of staining (or 'cut-off') required to qualify as a PD-L1-positive tumor and timing of sample collection (archival or immediately pre-treatment) varied across studies. Thus, while these preliminary findings are encouraging, data on tumor PD-L1 expression as a potential predictive biomarker are evolving, and prospective validation will be needed.Table 5PD-L1 expression and association with clinical activity \[[@CR11], [@CR12], [@CR14], [@CR22], [@CR28], [@CR29], [@CR39], [@CR56]--[@CR59]\]AgentSettingCut-off for PD-L1^+a^ORR in pts with PD-L1^+^ tumors, % (*n*/*N*)ORR in pts with PD-L1^-^low/negative tumors, % (*n/N*)Median PFS in pts with PD-L1^+^ tumorsMedian PFS in pts with PD-L1^−^ low/negative tumorsReference(s)PembrolizumabAdvanced melanoma≥1 %^b^51 (ND)6 (ND)12 months3 months\[[@CR56]\]PembrolizumabAdvanced NSCLC≥50 %^b^37 (15/41)11 (10/88)14.0 weeks9.3 weeks\[[@CR57]\]NivolumabPreviously-treated melanoma≥5 %^b^44 (8/18)13 (3/23)9 months2 months\[[@CR22]\]NivolumabPreviously-treated NSCLC≥5 %^b^15 (5/33)14 (5/35)3.6 months1.8 months\[[@CR28]\]NivolumabCTX-naïve NSCLC≥5 %^b^50 (5/10)0 (0/7)45.6 weeks36.1 weeks\[[@CR29]\]NivolumabRCC≥5 %^b^22 (4/18)8 (3/38)NDND\[[@CR58]\]MPDL3280APreviously-treated NSCLCScore = 3 (highly positive)^c^83 (5/6)20 (4/20)NDND\[[@CR39], [@CR59]\]MPDL3280ARCCPositive staining^c^20 (2/10)10 (2/21)NDND\[[@CR11], [@CR59]\]MPDL3280AUrothelial bladder cancer≥5 %^d^43 (ND)11 (ND)NDND\[[@CR12]\]MEDI4736NSCLCUndefined39 (5/13)5 (1/19)NDND\[[@CR14]\]MEDI4736Head and neck cancerUndefined50 (2/4)6 (1/16)NDND\[[@CR14]\]*CTX* chemotherapy, *ND* no data, *NSCLC* non-small cell lung cancer, *RCC* renal cell carcinoma, *PD-L1* programmed death ligand 1, *pts* patients^a^Amount of staining required to qualify as a PD-L1^+^ tumor^b^Membrane staining of tumor cells^c^Staining of tumor-infiltrating immune cells; amount of staining to qualify as a PD-L1^+^ tumor was not defined^d^Staining of tumor-infiltrating immune cells

Immunotherapy Clinical Response Patterns {#Sec22}
========================================

Across the various immunotherapy clinical development programs, investigators have observed response patterns that sometimes differ from the conventional responses observed with cytotoxic agents. Standard response criteria may not capture or adequately describe the responses produced by novel immunotherapy; thus, clinical trials may not always capture the full clinical benefit to patients who receive immunotherapy. To better characterize this pattern of response, new irRC were created that accounted for antitumor response based on total measurable tumor burden as measured by the sum of index lesions and new measurable lesions \[[@CR46]\]. Time point response assessment was also incorporated into the criteria, as two observations at least 4 weeks apart were necessary to help distinguish progression from 'pseudoprogression', in which there is an initial increase in tumor size followed by tumor shrinkage. The differences between World Health Organization (WHO) criteria and the new irRC are listed in Table [6](#Tab6){ref-type="table"} \[[@CR46]\].Table 6Comparison between WHO criteria and the irRC \[[@CR46]\]WHOirRCNew, measurable lesions (i.e., ≥5 × 5 mm)Always represent PDIncorporated into tumor burdenNew, non-measurable lesions (i.e., \<5 × 5 mm)Always represent PDDo not define progression (but preclude irCR)Non-index lesionsChanges contribute to defining BOR of CR, PR, SD, and PDContribute to defining irCR (complete disappearance required)CRDisappearance of all lesions in two consecutive observations not less than 4 weeks apartDisappearance of all lesions in two consecutive observations not less than 4 weeks apartPR≥50 % decrease in SPD of all index lesions vs. baseline in two observations at least 4 weeks apart, in absence of new lesions or unequivocal progression of non-index lesions≥50 % decrease in tumor burden vs. baseline in two observations at least 4 weeks apartSD50 % decrease in SPD vs. baseline cannot be established nor 25 % increase vs. nadir, in absence of new lesions or unequivocal progression of non-index lesions50 % decrease in tumor burden vs. baseline cannot be established nor 25 % increase vs. nadirPDAt least 25 % increase in SPD vs. nadir and/or unequivocal progression of non-index lesions and/or appearance of new lesions (at any single time point)At least 25 % increase in tumor burden vs. nadir (at any single time point) in two consecutive observations at least 4 weeks apartReproduced with permission from Wolchok et al. \[[@CR46]\]*BOR* best overall response, *CR* complete response, *irCR* immune-related complete response, *PD* progressive disease, *PR* partial response, *SD* stable disease, *SPD* sum of the products of the two largest perpendicular diameters, *WHO* World Health Organization

It has also been determined that some of these new response patterns to immune therapies are associated with a favorable survival outcome and may include the following:Stable disease, which in some cases may be followed by slow and steady decline of tumor burden. Durable, stable disease lasting months or even years has been observed in some patients.Reduction after an initial increase in tumor burden; this observation has been associated with T-cell infiltration into the tumor, giving the appearance of progressive disease.Reduction in total tumor burden during or after the appearance of new lesions, possibly due to the unique mechanism of action of immunotherapy, as the activated immune system may take some time to mount an effective antitumor response.

Time to response appears to be faster for agents that block PD-1 or PD-L1 compared with the many weeks it may take to observe tumor shrinkage in response to anti-CTLA-4 treatment \[[@CR8], [@CR13], [@CR21], [@CR38], [@CR46]\]. Additionally, response rates in patients given anti-PD-1 or anti-PD-L1 treatment may be higher than in those receiving anti-CTLA-4, although head-to-head trial data are not yet available.

Other Immune Targets---Inhibitory and Stimulatory {#Sec23}
=================================================

In addition to CTLA-4 and PD-1, other classes of inhibitory and stimulatory molecules have potential to be used as anticancer immunotherapy. One inhibitory molecule that has drawn much attention recently is lymphocyte activation gene-3 (LAG-3), a CD4 homolog that binds to MHC class II molecules (Fig. [1](#Fig1){ref-type="fig"}). LAG-3 is expressed on activated CD4^+^ and CD8^+^ T cells, as well as B cells, natural killer cells, and tumor-infiltrating lymphocytes, and is thought to negatively regulate T-cell expansion by limiting T-cell activation. However, LAG-3 knockout mice do not develop overt autoimmunity, suggesting that it plays a more subtle role in regulating T-cell function than the checkpoint molecules CTLA-4 and PD-1 \[[@CR3], [@CR60]\]. While LAG-3 is another immune checkpoint that may be important in the immune response to cancer, blockade of this pathway has not been clinically evaluated to the same extent as the CTLA-4 and PD-1 pathways \[[@CR3]\]. However, based on the success of other checkpoint molecules as targets for anticancer therapy, research is now ongoing to assess the possible clinical value of LAG-3 blockade. IMP321 is a soluble LAG-3 Ig fusion protein and MHC class II agonist (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR16]\]); it has been combined with gemcitabine in a phase I study in patients with advanced pancreatic adenocarcinoma \[[@CR15]\]. IMP321 plus gemcitabine appears to be a well tolerated regimen that has not resulted in any serious AEs in patients to date; however, limited antitumor responses were attributed to the low doses of IMP321. A small study combining IMP321 and melanoma-associated antigen immunization in patients with melanoma is ongoing (NCT01308294).

A variety of other molecules that similarly regulate T-cell activation, tolerance/exhaustion, anergy, and even T-cell death are currently being assessed as potential targets for anticancer therapy. One of these inhibitory molecules is T-cell immunoglobulin and mucin domain 3 (TIM3), which is a member of the TIM family (Fig. [1](#Fig1){ref-type="fig"}). TIM3 is expressed by IFN-γ-secreting helper T (T~H~1) cells, as well as dendritic cells, monocytes, and T cells \[[@CR61]\]. When bound to its ligand, galectin-9, TIM3 induces T~H~1 cell death \[[@CR62]\]. Studies of TIM3-deficient mice suggest that the TIM3 pathway inhibits the expansion and effector functions of T~H~1 cells and may be important for tolerance induction of T~H~1 cells \[[@CR63]\]. Administration of a TIM3 fusion protein resulted in hyperproliferation of T~H~1 cells and inflammatory cytokine release, suggesting a ligand for TIM3 is also expressed by these cells.

Glucocorticoid-induced TNF receptor-related gene (GITR) can provide a co-stimulatory signal to both CD4^+^- and CD8^+^-naïve T-cells, particularly when T-cell receptor stimulation is weak \[[@CR64]\] (Fig. [1](#Fig1){ref-type="fig"}). T cells that do not express GITR are more prone to activation-induced cell death, suggesting that GITR-mediated stimulation may enhance the survival of activated T cells. Also, preclinical studies showed that agonist anti-GITR antibodies could reverse regulatory T-cell suppression of effector T cells. Data from murine models suggest that GITR blockade may be most effective when combined with melanoma vaccination strategies and not as monotherapy \[[@CR65]\]. Currently, a phase I dose-escalation trial of an anti-GITR monoclonal antibody (TRX518) is recruiting patients with unresectable stage III or IV melanoma or other solid tumor malignancies (NCT01239134).

Combination Strategies {#Sec24}
======================

Despite promising results as monotherapies, there remains a clear need to increase the number of patients with malignancies that can benefit from immune checkpoint inhibitors. The increasing arsenal of targeted and immune-based therapies affords opportunities for sequencing and combination strategies to improve outcomes. Indeed, rapid and deep tumor regression was observed in a substantial number of patients when the CTLA-4 inhibitor, ipilimumab, was administered concurrently with nivolumab \[[@CR24]\]. In this study, 42 % of patients had ≥80 % tumor reduction at 36 weeks, and 1- and 2-year survival rates were 85 and 79 %, respectively. Though the efficacy appeared to be increased as compared with either drug alone, so did the rate of AEs. The observed toxicities were similar to those reported with monotherapy, albeit with higher incidence, including 62 % of patients experiencing grade 3/4 AEs. Other anti-CTLA-4 plus anti-PD-1 trials are ongoing, as are trials exploring dual blockade of the PD-1 pathway (anti-PD-1 plus anti-PD-L1) \[[@CR16]\]. Additional trials that are planned or have already entered the clinic include combinations of PD-1 pathway inhibitors with LAG-3, indolamine 2,3-dioxygenase 1 (IDO1), sipuleucel-T, or other vaccinations. Immune checkpoint inhibitor combinations with T-cell agonists (i.e., anti-CD40, anti-CD27, and anti-4-1BB) and with other immunostimulants (i.e., IFN, IL-21, and anti-killer immunoglobulin-like receptor \[KIR\]) are also underway.

It has been postulated that targeted agents and/or cytotoxic chemotherapy that effectively destroy tumor cells may increase circulating tumor antigens and, therefore, increase the immunogenic response and utility of checkpoint inhibitors \[[@CR35]\]. In fact, inhibition of mitogen-activated protein kinase with BRAF and/or MEK inhibitors in melanoma cells has been shown to modulate the functions of immune cells in preclinical studies \[[@CR66]\]. While a phase I/II study (NCT01400451) evaluating the safety and efficacy of combining vemurafenib with ipilimumab recently closed due to hepatic toxicity, a phase II study of vemurafenib followed by sequential ipilimumab in patients with V600 BRAF-mutated melanoma is still ongoing. Initial reports from phase I trials combining nivolumab with vascular endothelial growth factor (VEGF)-targeted therapies (sunitinib or pazopanib) are currently under study to determine the best dose and schedule \[[@CR67], [@CR68]\]. A combination regimen of pidilizumab (3 mg/kg) plus rituximab (375 mg/m^2^) has also been investigated in a phase II trial in patients with relapsed follicular lymphoma. Of 29 patients evaluable for efficacy, 19 had an objective response (66 %), 15 had a complete response (52 %), and four had a partial response (14 %) \[[@CR69]\].

Trials using ipilimumab combined with various cytotoxic chemotherapies, such as temozolomide plus doxycycline (NCT01590082) or fotemustine (NCT01654692) are underway in patients with metastatic melanoma, as are numerous trials of PD-1 pathway inhibitors plus chemotherapy or targeted agents \[[@CR16]\]. Trials evaluating ipilimumab plus paclitaxel/carboplatin (NCT01165216) and pembrolizumab or nivolumab plus chemotherapy or targeted agents (NCT02039674; NCT01454102) have been started in patients with NSCLC. Details on ongoing phase II and III trials investigating combination regimens with immune checkpoint inhibitors are provided in Table [3](#Tab3){ref-type="table"} \[[@CR16]\].

Conclusion {#Sec25}
==========

A better understanding of tumor immunology and immunotherapy, both at the bench and at the bedside, has led to a new and promising area of basic and clinical cancer research. Inhibitors of immune checkpoint regulators have in some cases led to deep and durable responses in patients with advanced malignancies. Many of the observed side effects are manageable and reversible following standard protocols.

Lessons learned from CTLA-4 and PD-1 blockade, in both the laboratory and the clinic, not only provide the foundation for a future era of superior immune checkpoint inhibition, but also provide a nidus of questions that remain unanswered. Furthering Virchow's initial observation and our understanding of the link between the immune system and malignancy, immune checkpoint inhibitors appear to offer new hope for cancer patients.
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